What smart money is saying about Stryker
1 fund in our archive has pitched Stryker — most recently Mar Vista U.S. Quality Portfolio in September 2026.
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
Get an email when a fund buys, sells or pitches it
Position history
Between Q2 2026 and Q4 2026, 14 fund letters reported a position in Stryker — 4 opened or added to the position, 3 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q4 2026 | 2 | 0 | 0 | 0 |
| Q3 2026 | 6 | 1 | 2 | 1 |
| Q2 2026 | 6 | 3 | 1 | 0 |
Fund activity · 14 positions · 7 moves
- October 2026
“Elsewhere, electrical company Legrand and medical technologies company Stryker detracted from performance on near-term concerns.”
Stryker - HoldsAcatisOctober 2026
“The fund fell by 3.3% in September. Rising interest rates and higher risk pre- miums weighed on the bond side. On the equity side, TSMC (+12.6%) continued to benefit from strong AI demand; August revenue was 53% above the previous year. Infineon (+4.9%) was newly added to the portfolio. With the sale of the NOR flash business for USD 1.12 billion, the company is focusing more strongly on structural growth areas such as power semiconductors and AI data centers. Alphabet (+3.8%) impressed with its strong position in the AI competition. Stryker (-12.7%) was weighed down by lingering supply bottlenecks and weaker hip implant sales, but confirmed its full-year guidance for organic growth.”
Stryker - September 2026
“Stryker (SYK) underperformed during the quarter primarily because investors lost confidence in the near-term growth trajectory, not because the long-term franchise deteriorated.”
Stryker - September 2026
“We exited positions in Cisco Systems in IT, Stryker in health care, Ferguson, Honeywell International and Honeywell Aerospace in industrials, Space Exploration Technologies, Walt Disney and T-Mobile in communication services and International Paper in materials.”
Stryker - September 2026
“Stryker is a medical technology company providing surgical equipment, instruments and implants across orthopedic and neurovascular markets.”
Stryker - New positionDiamond Hill Long-Short FundSeptember 2026
“New positions Long Portfolio • Stryker is a medical technology company providing surgical equipment, instruments and implants across orthopedic and neurovascular markets. We initiated a position given the company’s broad product portfolio, consistent innovation and strong commercial execution, which we believe position Stryker to continue gaining market share and delivering above-market growth.”
Stryker - September 2026
“We reduced our position during the quarter to account for the increased operational risks but continue to own Stryker given its durable competitive advantages, leading market positions, strong innovation pipeline, and attractive long-term growth opportunities.”
Stryker - September 2026
“• Meta Platforms is the world’s largest social media company and operates several applications, including Facebook, Instagram, Messenger, WhatsApp and Threads, serving more than 3.5 billion daily active users. We initiated a position as we believe the market is underappreciating the company’s accelerating core advertising business and broad distribution advantages, creating an attractive entry point from a valuation perspective. • Stryker is a medical technology company providing surgical equipment, instruments and implants across orthopedic and neurovascular markets.”
Stryker - June 2026
“We added quality names including Stryker (SYK), Adyen (ADYEN NA) and Booking.com (BKNG).”
Stryker - ExitedBaron Health Care FundJune 2026
“Top net sales for the quarter Net Amount Sold ($M) AstraZeneca PLC 3.0 Ionis Pharmaceuticals, Inc. 2.3 Apogee Therapeutics, Inc. 2.0 Terns Pharmaceuticals, Inc. 1.8 Stryker Corporation 1.7 We reduced our positions in AstraZeneca PLC and Ionis Pharmaceuticals, Inc. due to valuation. We sold Apogee Therapeutics, Inc. and Terns Pharmaceuticals, Inc. following announcements that they were being acquired, Apogee by AbbVie Inc. and Terns by Merck & Co., Inc. , another Fund holding . We sold Stryker Corporation because of concerns about slowing hospital inpatient trends and hospital capex spending due to expiration of the ACA subsidies and stricter Medicaid eligibility requirements.”
Stryker - June 2026
“Quality compounders form the foundation of the Portfolio and include Stryker (SYK), Mastercard (MA), Aon PLC (AON), and Sherwin-Williams (SHW),”
Stryker “Quality compounders form the foundation of the Portfolio and include Stryker (SYK), Mastercard (MA), Marsh (MRSH), and Sherwin- Williams (SHW).”
Stryker- June 2026
“SouthState Bank is a regional bank with $68 billion in assets with key markets in South Carolina, Florida, Georgia, Texas and Colorado. SouthState generates strong returns and is trading at an attractive valuation given it underlying business fundamentals. Stryker is a medical technology company that offers innovative products and services in MedSurg, Neurotechnology and Orthopedics. After experiencing a cybersecurity attack in the first quarter, Stryker reported weak first quarter earnings due to the attack but maintained guidance for the full year. The stock continued to underperform, creating the opportunity to purchase a high-quality healthcare company at a reduced valuation.”
Stryker - New positionRIT Capital PartnersJune 2026
“This capital was redeployed into new positions in Stryker, a med-tech company, at an attractive entry point, and Allegion, who manufacture innovative entry-access hardware and technology.”
Stryker
Fund coverage · 1 thesis
- Mar Vista U.S. Quality PortfolioSeptember 2026
Stryker faces temporary growth and execution issues, but procedure demand remains healthy and long-term free cash flow growth appears undervalued.
Read the full thesis
Read every full thesis on Stryker
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→